Why the study?
Does a recombinant adenovirus FMD vaccine protect swine and cattle from FMD clinical signs and viral replication?
Does a recombinant adenovirus FMD vaccine protect swine and cattle from FMD clinical signs and viral replication?
Answers are grounded in this paper and cite their sources.
A novel recombinant adenovirus-based FMD vaccine shows promise in protecting swine and cattle from clinical disease and viral replication.
Inactivated foot and mouth disease (FMD) vaccines have been used successfully as part of eradication programmes. However, there are a number of concerns with the use of such vaccines and the recent outbreaks of FMD in disease-free countries have increased the need for improved FMD control strategies. To address this requirement, new generation FMD vaccines are being developed. Currently, one of the most promising of these vaccine candidates utilises an empty viral capsid subunit delivered to animals by a live virus vector. This candidate, a replication-defective recombinant human adenovirus containing the capsid and 3C proteinase coding regions of FMD virus (FMDV), induces an FMDV-specific neutralising antibody response in inoculated animals. Upon challenge with a virulent animal-passaged homologous virus, swine and cattle vaccinated with this recombinant adenovirus are protected from clinical signs of FMD as well as from FMDV replication. One inoculation of a high dose of this vaccine candidate protected swine from challenge as early as seven days after vaccination.
No takes yet. Share an insight, caveat, or question.
Grubman et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: